Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated claim is directly supported by Eliquis FDA labeling for increased thrombotic risk after premature discontinuation (5.1) and for spinal/epidural hematoma risk and potential long-term/permanent paralysis with neuraxial anesthesia or spinal/epidural puncture (5.3), with no contradictions or material omissions identified.
Category Scores
Accurate Statements
Premature discontinuation of Eliquis increases the risk of thrombotic events (including stroke during transition to warfarin).
Supported by Warnings and Precautions 5.1 (increased thrombotic risk with premature discontinuation; increased rate of stroke observed during transition from ELIQUIS to warfarin in atrial fibrillation trials).
Neuraxial anesthesia/spinal or epidural puncture while on antithrombotic therapy increases the risk of epidural/spinal hematoma that can cause long-term or permanent paralysis.
Supported by Warnings and Precautions 5.3 (risk of epidural/spinal hematoma; can result in long-term or permanent paralysis).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim reflects on-label risk statements from Eliquis labeling (5.1 and 5.3) without adding unsupported safety assertions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement